Stepen oštećenja jetre kod neoadjuvantne terapije metastatskog kolorektalnog karcinoma

Abstract

The study included 90 patients operated for colorectal cancer with liver metastases, divided into three groups. In the first group (G1) were patients who received FOLFOX IV neoadjuvant therapy, while in the second group (G2) biological agent bevacizumab was added to FOLFOX IV. The third group was the control group without chemotherapy. Biochemical parameters of metabolic syndrome (MS) and liver damage were followed. Liver steatosis and sinusoidal obstructive syndrome (SOS) were assesed by pathohystological examination. Steatosis liver injury in pathohystology was found in 56.7 % of patients in G1, 3.3 % in G2 and in 40% in the control group. Independent risk factors for degree of statosis were triglycerides, HDL and BMI. MS was present in 75% of patients in G1, which was significantly higher in comparison to G2 (27%). SOS was registered in 66.7 % in G2, 6.7 % in G1, while it was not registered in the control group. Independent risk factors for liver SOS were the following parameters of MS: triglycerides and HDL.